Market Update (NASDAQ:REGN): EYLEA® (aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment Due to Macular Edema Secondary to Central or Branch Retinal Vein Occlusion in the European Union

[PR Newswire] – TARRYTOWN, N.Y., Jan. 23, 2015 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that EYLEA ® (aflibercept) Injection has been recommended for approval by the European Committee … Read . . . → Read More: Market Update (NASDAQ:REGN): EYLEA® (aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment Due to Macular Edema Secondary to Central or Branch Retinal Vein Occlusion in the European Union Similar Articles: Market Update (NASDAQ:REGN): EYLEA® (aflibercept) Injection Accepted for Priority Review by FDA for Diabetic Retinopathy in Patients with Diabetic Macular Edema Stock Update (NASDAQ:REGN): EYLEA® (aflibercept) Injection Receives FDA Approval for Macular Edema Following Retinal Vein Occlusion (RVO) Market Update: Regeneron Pharmaceuticals Inc (NASDAQ:REGN) – EYLEA® (aflibercept) Injection Receives FDA Breakthrough Therapy Designation for Diabetic Retinopathy in Patients with Diabetic Macular Edema